{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:43:04Z","timestamp":1793241784889,"version":"4.5.0"},"reference-count":29,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Emicizumab is approved for prophylaxis of patients with hemophilia A (HA). Despite its efficacy in reducing bleeding, some patients on emicizumab still experience hemarthrosis, but no tool is yet available to identify those at a higher risk of spontaneous joint bleeding. This study aimed to evaluate whether laboratory measurements (global coagulation assays and emicizumab concentration) and\/or arthropathy scores can distinguish patients at higher risk of spontaneous joint bleeding while on emicizumab prophylaxis. A thrombin generation assay was performed upon the addition of tissue factor and synthetic phospholipids. Nonactivated thromboelastography was performed on citrated whole blood. Emicizumab concentrations were measured using a modified 1-stage factor VIII assay. The degree of hemophilic arthropathy was assessed using the Hemophilia Joint Health Score and Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) score. A Cox proportional hazards model was used to evaluate the association between variables and bleeding. The predictive power of these variables was investigated using receiver operating characteristic (ROC) analysis. Forty patients with severe HA, with or without inhibitors, on emicizumab prophylaxis were enrolled in an observational cohort study. Ten of 40 developed spontaneous joint bleeding. None of the laboratory parameters were able to distinguish patients with a higher risk of spontaneous joint bleeding. ROC analysis showed that during emicizumab prophylaxis, only the presence of synovitis and a higher HEAD-US score were associated with spontaneous joint bleeding (area under the curve, 0.84). A greater degree of arthropathy and the presence of synovitis could help predict the risk of spontaneous joint bleeding in patients with HA on emicizumab prophylaxis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023012285","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T21:00:08Z","timestamp":1711486808000},"page":"2901-2907","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5743-9098","authenticated-orcid":false,"given":"Sara","family":"Arcudi","sequence":"first","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-7624","authenticated-orcid":false,"given":"Roberta","family":"Gualtierotti","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"2Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6286-6924","authenticated-orcid":false,"given":"Erica","family":"Scalambrino","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0194-3962","authenticated-orcid":false,"given":"Marigrazia","family":"Clerici","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-636X","authenticated-orcid":false,"given":"Shermarke","family":"Hassan","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"3Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Begnozzi","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena Anna","family":"Boccalandro","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Novembrino","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-0119","authenticated-orcid":false,"given":"Carla","family":"Valsecchi","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-2367","authenticated-orcid":false,"given":"Roberta","family":"Palla","sequence":"additional","affiliation":[{"name":"2Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"1Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"},{"name":"2Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"3","key":"2024061015505630800_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtha.2022.12.029","article-title":"Hemophilia treatment innovation: 50 years of progress and more to come","volume":"21","author":"Mannucci","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"issue":"10","key":"2024061015505630800_bib2","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1111\/jth.14242","article-title":"Nano-evidence for joint microbleeds in hemophilia patients","volume":"16","author":"Puetz","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024061015505630800_bib3","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/jth.15640","article-title":"Thrombin generation for monitoring hemostatic therapy in hemophilia A: a narrative review","volume":"20","author":"Verhagen","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"issue":"9","key":"2024061015505630800_bib4","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia a with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"2024061015505630800_bib5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multi- center, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"9","key":"2024061015505630800_bib6","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2024061015505630800_bib7","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3026(19)30054-7","article-title":"Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4\u00a0weeks in people with hemophilia A (HAVEN 4): a multicenter, open-label, non-randomized phase 3 study","volume":"6","author":"Pipe","year":"2019","journal-title":"Lancet Haematol"},{"issue":"3","key":"2024061015505630800_bib8","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1055\/s-0040-1717114","article-title":"Pharmacokinetics and pharmacodynamics of Emicizumab in persons with Hemophilia A with factor VIII inhibitors: HAVEN 1 Study","volume":"121","author":"Schmitt","year":"2021","journal-title":"Thromb Haemost"},{"issue":"16","key":"2024061015505630800_bib9","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1182\/blood.2020009217","article-title":"Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies","volume":"137","author":"Callaghan","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024061015505630800_bib10","doi-asserted-by":"crossref","first-page":"e12571","DOI":"10.1002\/rth2.12571","article-title":"Emicizumab initiation and bleeding outcomes in people with hemophilia A with and without inhibitors: a single-center report","volume":"5","author":"Warren","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"10","key":"2024061015505630800_bib11","doi-asserted-by":"crossref","first-page":"E285","DOI":"10.1002\/ajh.27039","article-title":"Severe muscle bleeds in children and young adults with hemophilia A on emicizumab prophylaxis: real-world retrospective multi-institutional cohort","volume":"98","author":"Batsuli","year":"2023","journal-title":"Am J Hematol"},{"issue":"9","key":"2024061015505630800_bib12","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1055\/s-0039-1692427","article-title":"Laboratory monitoring in emicizumab-treated persons with hemophilia A","volume":"119","author":"M\u00fcller","year":"2019","journal-title":"Thromb Haemost"},{"issue":"4","key":"2024061015505630800_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12185-019-02698-8","article-title":"Global coagulation function assessed by rotational thromboelastometry predicts coagulation-steady state in individual hemophilia A patients receiving emicizumab prophylaxis","volume":"110","author":"Yada","year":"2019","journal-title":"Int J Hematol"},{"issue":"4","key":"2024061015505630800_bib14","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1111\/hae.14330","article-title":"Thromboelastometry detects enhancement of coagulation in blood by emicizumab via intrinsic pathway","volume":"27","author":"Szanto","year":"2021","journal-title":"Haemophilia"},{"issue":"3","key":"2024061015505630800_bib15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.14318","article-title":"Emicizumab prophylaxis: prospective longitudinal real-world follow-up and monitoring","volume":"27","author":"Barg","year":"2021","journal-title":"Haemophilia"},{"issue":"4","key":"2024061015505630800_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s12185-021-03276-7","article-title":"Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients","volume":"115","author":"Nakajima","year":"2022","journal-title":"Int J Hematol"},{"issue":"3","key":"2024061015505630800_bib17","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/17474086.2018.1435269","article-title":"The value of HEAD-US system in detecting subclinical abnormalities in joints of patients with hemophilia","volume":"11","author":"De la Corte-Rodriguez","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2024061015505630800_bib18","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1515\/cclm-2020-0696","article-title":"Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma","volume":"59","author":"Tripodi","year":"2020","journal-title":"Clin Chem Lab Med"},{"issue":"1","key":"2024061015505630800_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"issue":"5","key":"2024061015505630800_bib20","first-page":"547","article-title":"Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability","volume":"88","author":"Chantarangkul","year":"2003","journal-title":"Haematologica"},{"issue":"8","key":"2024061015505630800_bib21","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1111\/jth.13743","article-title":"Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH","volume":"15","author":"Dargaud","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"issue":"5","key":"2024061015505630800_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1373\/clinchem.2015.248625","article-title":"Thrombin generation assay and its application in the clinical laboratory","volume":"62","author":"Tripodi","year":"2016","journal-title":"Clin Chem"},{"issue":"6","key":"2024061015505630800_bib23","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1160\/TH12-11-0874","article-title":"Development and definition of a simplified scanning procedure and scoring method for hemophilia early arthropathy detection with ultrasound (HEAD-US)","volume":"109","author":"Martinoli","year":"2013","journal-title":"Thromb Haemost"},{"issue":"8","key":"2024061015505630800_bib24","first-page":"77","article-title":"Ultrasound for early detection of joint disease in patients with hemophilic arthropathy","volume":"6","author":"Di Minno","year":"2017","journal-title":"J\u00a0Clin Med"},{"issue":"19","key":"2024061015505630800_bib25","first-page":"4303","article-title":"Real-world data on bleeding patterns of hemophilia A patients treated with emicizumab","volume":"10","author":"Levy-Mendelovich","year":"2021","journal-title":"J\u00a0Clin Med"},{"issue":"9","key":"2024061015505630800_bib26","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"4","key":"2024061015505630800_bib27","doi-asserted-by":"crossref","first-page":"e0248952","DOI":"10.1371\/journal.pone.0248952","article-title":"Correlation between hemophilia early arthropathy detection with ultrasound (HEAD-US) score and hemophilia joint health score (HJHS) in patients with hemophilic arthropathy","volume":"16","author":"Prasetyo","year":"2021","journal-title":"PLoS One"},{"key":"2024061015505630800_bib28","doi-asserted-by":"crossref","first-page":"541","DOI":"10.3389\/fphys.2020.00541","article-title":"Pathophysiological role of synovitis in hemophilic arthropathy development: a two-hit hypothesis","volume":"11","author":"Calcaterra","year":"2020","journal-title":"Front Physiol"},{"issue":"6","key":"2024061015505630800_bib29","doi-asserted-by":"crossref","first-page":"e12782","DOI":"10.1002\/rth2.12782","article-title":"Untreated bleeds in people with hemophilia A in a noninterventional study and interpatient comparison after initiating emicizumab in HAVEN 1\u20133","volume":"6","author":"Callaghan","year":"2022","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2901\/2228393\/blooda_adv-2023-012285-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2901\/2228393\/blooda_adv-2023-012285-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T15:51:25Z","timestamp":1718034685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2901\/515502\/Predictive-parameters-for-spontaneous-joint"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023012285","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}